리젠케어

비상장계속사업자

regencare co.,Ltd

손태식

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

리젠케어

Business Reg. No. 2118893543 · CEO 손태식

I.Investment Overview

Target리젠케어 (2118893543)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명리젠케어
영문명regencare co.,Ltd
대표자손태식
사업자등록번호2118893543
법인등록번호1101115108299
설립일2013.04.29

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW17.1202122.5202235.8202337.7202443.22025
영업이익100M KRW-6.32021-1.220226.220237.620248.82025
순이익100M KRW-9.42021-5.920220.420232.520244.52025
Item20252024202320222021
자산총계113.8억원120.9억원122억원123.2억원125.6억원
부채총계99억원110.6억원114.2억원115.8억원112.3억원
자본총계14.8억원10.3억원7.8억원7.4억원13.3억원
매출액43.2억원37.7억원35.8억원22.5억원17.1억원
영업이익8.8억원7.6억원6.2억원-1.2억원-6.3억원
순이익4.5억원2.5억원3,577만원-5.9억원-9.4억원

VI.Financial Ratios

FY2025 basis

20.47%

영업이익률

10.36%

순이익률

3.93%

ROA

30.27%

ROE

670.2%

부채비율

12.98%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

리젠케어 투심보고서 | Alpha Lenz